Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study

Osteoporosis International

Volumn 9, Issue 5, 1999, Pages 461-468

  Pols, H A P ^a   Felsenberg, D ^b   Hanley, D A ^c   Stepan J ^d   Munoz Torres M ^e   Wilkin, T J ^f   Qin Sheng, G ^g   Galich, A M ^h   Vandormael, K ⁱ   Yates, A J ⁱ   Stych, B ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF CALGARY   (Canada)

^d CHARLES UNIVERSITY   (Czech Republic)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^f Freedom Fields Hospital   (United Kingdom)

^g PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^h HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Bisphosphonate; Bone mineral density; Fractures; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FEMUR NECK; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; CREATININE; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 0032896590     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004171     Document Type: Article

References (20)

1. Melton LJ III. How many women have osteoporosis now? J Bone Miner Res 1995;10:175-7.
2. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
3. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10.
4. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-7.
5. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late-postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
6. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993;53:283-8.
7. Balena R, Markatos A, Seedor JG, et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J. Pharmacol Exp Ther 1996;276:277-83.
8. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhman primates. J Clin Invest 1993;92:2577-86.
9. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
10. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
11. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
12. Hanson DA, Weiss MAE, Bollen AM, Maslan SH, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen crosslinked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
13. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
14. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
15. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
16. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of non-vertebral fractures by alendronate: a meta-analysis. JAMA 1997;277:1159-64.
17. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
18. Kotowicz MA, Melton LJ III, Cooper C, Atkinson EJ, O'Fallon WM, Riggs BL. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 1994;9:599-605.
19. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165-77.
20. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.